All In Biotech

Drug Trial Radar · NCT01950247

Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron

Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on QOL and Resource Utilization, of Injectafer® vs. IV Iron Standard of Care for the Treatment of IDA in an Infusion Center

Last checked: Nov 20, 2026Latest source record: May 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,025 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,025

Actual

Start

Aug 15, 2013

Primary completion

May 20, 2015

Study completion Jun 2015

Sponsor

Lead sponsor
American Regent, Inc.Industry
Sponsor type
Industry
First posted
Sep 25, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of this study is to compare the safety, effect on quality of life, and resource utilization of Injectafer vs. intravenous (IV) iron standard of care (SOC) for the treatment of iron deficiency anemia (IDA) in an infusion center setting. The study will also assess the ability of baseline serum hepcidin levels to predict if subjects will have a clinically meaningful hemoglobin response to oral iron therapy or to IV iron therapy.

Conditions

  • Iron Deficiency Anemia (IDA)

Interventions

  • InjectaferDrug

    2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.

  • SOCDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Multidimensional Assessment of Fatigue (MAF) ScoresTime frame: Baseline to Day 30
  2. Work Productivity and Activity Impairment Questionnaire (WPAI) ScoresTime frame: Baseline and Day 30
  3. Treatment Satisfaction Questionnaire for Medication Version 1.4 ScoresTime frame: Baseline and Day 30
  4. Short Form Health Survey, 12-Item (SF-12) v2 Quality of Life Scores.Time frame: Baseline and Day 30

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.